{"title":"Increased Cerebrospinal Fluid Adenosine 5'-Triphosphate Levels in Patients with Guillain-Barré Syndrome and Chronic Inflammatory Demyelinating Polyneuropathy.","authors":"Takamasa Nukui, Hideki Niimi, Tomohiro Hayashi, Nobuhiro Dougu, Mamoru Yamamoto, Ryoko Shibuya, Noriyuki Matsuda, Ryo Tanaka, Hiroaki Hirosawa, Risako Furuta, Taichi Mitsui, Hiroki Maesaka, Syuhei Takasawa, Isao Kitajima, Yuji Nakatsuji","doi":"10.1155/2024/7229216","DOIUrl":"10.1155/2024/7229216","url":null,"abstract":"<p><strong>Background: </strong>Extracellular adenosine 5'-triphosphate (ATP) acts as a signaling molecule in the peripheral nerves, regulating myelination after nerve injury. The present study examined whether the cerebrospinal fluid (CSF) ATP levels in patients with Guillain-Barré syndrome (GBS) and chronic inflammatory demyelinating polyneuropathy (CIDP) are related to disease severity.</p><p><strong>Methods: </strong>CSF ATP levels in 13 patients with GBS and 18 patients with CIDP were compared with those in a control group of 16 patients with other neurological diseases (ONDs). In patients with CIDP, CSF ATP levels were compared before and after treatment. The correlations between CSF ATP levels and other factors, including clinical data and CSF protein levels, were also evaluated.</p><p><strong>Results: </strong>Median CSF ATP levels were significantly higher in patients with GBS and CIDP than in those with ONDs. When patients with CIDP were classified into two groups depending on their responsiveness to immunotherapy, median CSF ATP levels were significantly higher in good responders than in ONDs. CSF ATP levels tended to decrease after treatment in patients with CIDP. In patients with CIDP, there is a negative correlation between CSF ATP and CSF protein levels.</p><p><strong>Conclusions: </strong>CSF ATP levels were increased in patients with GBS and CIDP. In particular, CSF ATP levels tended to decrease following treatment in patients with CIDP. CSF ATP levels may be useful biomarkers for the diagnosis or monitoring of therapeutic effects in patients with GBS and CIDP.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11182687/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141420062","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Glucometabolic-Related Genes as Diagnostic Biomarkers and Therapeutic Targets for Alzheimer's Disease and Type 2 Diabetes Mellitus: A Bioinformatics Analysis","authors":"Shuo Liu, He Chen, Xiaojuan He, Xiao-Ou Yang","doi":"10.1155/2024/5200222","DOIUrl":"https://doi.org/10.1155/2024/5200222","url":null,"abstract":"Background Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) are two widespread chronic disorders characterized by shared risk factors and molecular pathways. Glucose metabolism, pivotal for cellular homeostasis and energy supply, plays a critical role in these diseases. Its disturbance has been linked to the pathogenesis of both AD and T2DM. However, a comprehensive investigation into the specific roles of glucometabolic genes in the onset and progression of AD and T2DM has yet to be conducted. Methods By analyzing microarray datasets from the Gene Expression Omnibus (GEO) repository, we identified differentially expressed glucometabolic genes (DEGs) in AD and T2DM cohorts. A range of bioinformatics tools were employed for functional annotation, pathway enrichment, protein interaction network construction, module analysis, ROC curve assessment, correlation matrix construction, gene set enrichment analysis, and gene-drug interaction mapping of these DEGs. Key genes were further validated using quantitative real-time polymerase chain reaction (qRT-PCR) in AD and T2DM murine models. Results Our investigation identified 41 glucometabolic-related DEGs, with six prominent genes (G6PD, PKM, ENO3, PFKL, PGD, and TALDO1) being common in both AD and T2DM cohorts. These genes play crucial roles in metabolic pathways including glycolysis, pentose phosphate pathway, and amino sugar metabolism. Their diagnostic potential was highlighted by area under curve (AUC) values exceeding 0.6 for AD and 0.8 for T2DM. Further analysis explored the interactions, pathway enrichments, regulatory mechanisms, and potential drug interactions of these key genes. In the AD murine model, quantitative real-time polymerase chain reaction (qRT-PCR) analysis revealed significant upregulation of G6pd, Eno3, and Taldo1. Similarly, in the T2DM murine model, elevated expression levels of G6pd, Pfkl, Eno3, and Pgd were observed. Conclusion Our rigorous research sheds light on the molecular interconnections between AD and T2DM from a glucometabolic perspective, revealing new opportunities for pharmacological innovation and therapeutic approaches. This study appears to be the first to extensively investigate glucometabolic-associated DEGs and key genes in both AD and T2DM, utilizing multiple datasets. These insights are set to enhance our understanding of the complex pathophysiology underlying these widespread chronic diseases.","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140755363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nassim Zekibakhsh Mohammadi, Amir Sam Kianimoghadam, Niloofar Mikaeili, Seyedeh Samaneh Asgharian, Mahdieh Jafari, Abbas Masjedi-Arani
{"title":"Sleep Disorders and Fatigue among Patients with MS: The Role of Depression, Stress, and Anxiety.","authors":"Nassim Zekibakhsh Mohammadi, Amir Sam Kianimoghadam, Niloofar Mikaeili, Seyedeh Samaneh Asgharian, Mahdieh Jafari, Abbas Masjedi-Arani","doi":"10.1155/2024/6776758","DOIUrl":"10.1155/2024/6776758","url":null,"abstract":"<p><p>Sleep disorders and fatigue represent prominent symptoms frequently experienced by individuals with multiple sclerosis (MS). Some psychological factors such as depression, stress, and anxiety seem to have a relationship with such problems. This study aimed to examine the role of depression, stress, and anxiety in predicting sleep disorders and fatigue among patients with MS. Employing a cross-sectional descriptive-correlational design, the study involved a sample size of 252 participants selected through purposive sampling based on inclusion and exclusion criteria. We utilized a demographic information questionnaire along with the Mini-Sleep Questionnaire (MSQ), Fatigue Severity Scale (FSS), and Depression, Anxiety, and Stress Scale (DASS-21) to collect data and analyzed them applying SPSS<sub>22</sub>, incorporating statistical measures including Pearson correlation and regression. The results of the Pearson correlation coefficient showed that sleep disorders had a positive and significant relationship with depression (<i>r</i> = 0.56; <i>P</i> < 0.001), stress (<i>r</i> = 0.40; <i>P</i> < 0.001), and anxiety (<i>r</i> = 0.52; <i>P</i> < 0.001). There was no significant relationship between age and the development of sleep disorders in total score (<i>r</i> = -0.001; <i>P</i> < 0.985), but age had a relationship with insomnia (<i>r</i> = -0.146; <i>P</i> < 0.021) and oversleeping (<i>r</i> = 0.153; <i>P</i> < 0.015). Age and fatigue did not have a significant relationship as well (<i>r</i> = -0.044; <i>P</i> < 0.941). In addition, fatigue had a positive and significant relationship with depression (<i>r</i> = 0.52; <i>P</i> < 0.001), stress (<i>r</i> = 0.48; <i>P</i> < 0.001), and anxiety (<i>r</i> = 0.54; <i>P</i> < 0.001). The results of the regression analysis also showed that depression, stress, and anxiety predict 0.37% of the total variance of sleep disorders (<i>F</i> = 48.34; <i>P</i> < 0.001) and 0.35% of the total variance of fatigue (<i>F</i> = 44.64; <i>P</i> < 0.001). Our findings suggest that depression, stress, and anxiety play a significant role in predicting sleep disorders and fatigue among patients with MS. This study has been reported in accordance with the TREND checklist for nonrandomized trials.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10843872/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139697949","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leila Beigom Hejazian, S. M. Hosseini, Alireza Salehi
{"title":"Neuroprotective Effects of Rosa damascena Extract against Aluminum Chloride-Induced Brain Damage in Rat Offspring","authors":"Leila Beigom Hejazian, S. M. Hosseini, Alireza Salehi","doi":"10.1155/2023/5342849","DOIUrl":"https://doi.org/10.1155/2023/5342849","url":null,"abstract":"Aluminum (Al) is a popular metal in the industry, and its usage has greatly increased recently. The dose of this metal has been proven to be toxic to rats, but its effects on the offspring of the original receivers and prevention methods to reduce this damage are unknown. Rosa damascena is a well-known plant for its high antioxidant capabilities. In this study, the protective effect of Rosa damascena extract (RDA) on aluminum-induced lesions in the brain tissue of a rat offspring was investigated. In this regard, female rats were divided into seven groups, including the control group, the sham group, the aluminum group at the dose of 100 mg/kg, the extract groups at the doses of 500 and 1000 mg/kg, and the treatment groups that received the extract and Al at the same doses. After the treatment ended, the offsprings were subjected to exploratory behavioral tests, and finally, the tissues of the brain including the cerebral cortex, hippocampus, and hypothalamus were pathologically examined. It was observed that RDA at the dose of 1000 mg/kg reduced the malondialdehyde (MDA) and acetylcholinesterase (AChE) levels significantly (P < 0.0001), while raising the catalase and FRAP indices in Al-treated rats. Moreover, it increased neuronal counts significantly and reduced necrosis and vacuolar degeneration in both the cortex and hippocampus compared to the Al-receiving group. In addition, the administration of RDA 1000 improved the behavioral test scores of the offspring. In conclusion, RDA can effectively reduce Al-induced damage in the brain tissue of the offspring.","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138604434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Sanaz Salaramoli, Hamid Reza Joshaghani, Seyed Isaac Hashemy
{"title":"Salivary Biomarkers: Noninvasive Ways for Diagnosis of Parkinson's Disease.","authors":"Sanaz Salaramoli, Hamid Reza Joshaghani, Seyed Isaac Hashemy","doi":"10.1155/2023/3555418","DOIUrl":"https://doi.org/10.1155/2023/3555418","url":null,"abstract":"<p><p>Finding reliable biomarkers has a crucial role in Parkinson's disease (PD) assessments. Saliva is a bodily fluid, which might be used as a source of biomarkers for PD. Our article has reviewed several publications on salivary proteins in PD patients and their potential as biomarkers. We find out that <i>α</i>-Syn's proportion in oligomeric form is higher in PD patients' saliva, which is potent to use as a biomarker for PD. The salivary concentration of DJ-1 and alpha-amylase is lower in PD patients. Also, substance P level is more moderate in PD patients. Although salivary flow rate is decreased in PD patients, high levels of heme oxygenase and acetylcholinesterase might be used as noninvasive biomarkers. Salivary miRNAs (miR-153, miR-223, miR-874, and miR-145-3p) are novel diagnostic biomarkers that should be given more attention.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10332915/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9869902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Item Selection for a New Health-Related Quality of Life Measure for Parkinson's Disease: The Preference-Based Parkinson's Disease Index (PB-PDI).","authors":"Selina Malouka, Lizabeth Teshler, Nancy Mayo, Marla Beauchamp, Julie Richardson, Ayse Kuspinar","doi":"10.1155/2023/6559857","DOIUrl":"https://doi.org/10.1155/2023/6559857","url":null,"abstract":"Background Parkinson's disease (PD) is a neurodegenerative condition, predominantly affecting older adults. Preference-based measures (PBMs) can be used to make decisions about the cost-utility of different treatments. There are currently no PBMs for health-related quality of life (HRQoL) for PD. A previous study identified important health domains for individuals with PD and developed an item pool from existing measures per domain. The current study aims to contribute to the development of a new disease-specific PBM of HRQoL for PD by reducing the current pool of items according to the preferences of individuals with PD. Methods Fifty-three participants completed a visual analogue scale (VAS) of self-perceived health, the prototype PBM measure, and an item importance rating. To reduce the item pool, the following were calculated: (1) inter-item correlations; (2) impact of each item based on item performance and importance rating; (3) directionality of response options by comparing the VAS scores against each item. Results Participants (male = 54.7%, age = 60.0 ± 10.2) had a median Hoehn and Yahr score of 2.5 (interquartile range = 1). Items supported for inclusion by this analysis were sleep, fatigue, tremor, mood, walking, memory, and dexterity. Items demonstrating a logical decrease in VAS score with each increasing severity level were sleep, memory, tremor, fatigue, and mood. Conclusion This PBM will be critical for informing decisions about the cost-utility of PD treatments, guiding the resource allocation within our healthcare system. Future research will include cognitive debriefing with individuals with PD to refine item response options.","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9876679/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10584407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Yaroslava Yu Havlovska, Nataliya V Lytvynenko, Anastasiia D Shkodina
{"title":"Serum Level of Brain-Derived Neurotrophic Factor and Thrombotic Type Are Predictive of Cognitive Impairment in the Acute Period of Ischemic Strokes Patients.","authors":"Yaroslava Yu Havlovska, Nataliya V Lytvynenko, Anastasiia D Shkodina","doi":"10.1155/2023/5578850","DOIUrl":"https://doi.org/10.1155/2023/5578850","url":null,"abstract":"<p><p>40-70% of patients after a stroke, including a mild one, may experience cognitive impairment. Brain-derived neurotrophic factor (BDNF) plays a significant role in the pathogenesis and rehabilitation of ischemic stroke and also affects the patients' recovery prognosis. An association between cognitive impairment in the poststroke period and lower peripheral BDNF levels is known, but the prognostic significance of serum BDNF levels and clinical characteristics for the risk of developing cognitive impairment in the acute period remains uncertain. We conducted a prospective cohort study of patients in the acute phase of ischemic stroke. Clinical examination, assessment of neurological status, neuropsychological testing, and laboratory analyzes were performed on patients at 1 and 14 days after ischemic stroke. The state of cognitive functions was assessed by the Mini-Mental State Examination scale. Quantification of BDNF in blood serum was performed by solid-phaseenzyme-linked immunosorbent assay (ELISA). We found that within 14 days after an acute ischemic stroke, we found a decrease in the clinical severity of patients compared to 1 day of the onset of the disease before the start of treatment and a significant decrease in the level of BDNF in the blood serum of patients with ischemic stroke both on the first and on the 14th day. However, during the 2 weeks of the acute period, no significant changes were detected, despite the general improvement of the clinical condition. In our study, cognitive impairment was found in almost half of the patients on the first day of ischemic stroke, and there was no significant reduction in this prevalence over 2 weeks. We found that a low level of BDNF and a thrombotic subtype of ischemic stroke can be risk factors for cognitive impairment in the acute period, which can be useful in planning treatment and rehabilitation measures.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10033208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9193629","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Correlation between the Neutrophil-to-Lymphocyte Ratio and Multiple Sclerosis: Recent Understanding and Potential Application Perspectives.","authors":"Qingqing Zhou, Rui Jia, Jingxia Dang","doi":"10.1155/2022/3265029","DOIUrl":"https://doi.org/10.1155/2022/3265029","url":null,"abstract":"<p><p>Multiple sclerosis (MS) is a chronic debilitating immune-mediated disease of the central nervous system, which causes demyelination and neuroaxonal damage. Low-grade systemic inflammation has been considered to lead to pathogenesis owing to the amplification of pathogenic immune response activation. However, there is a shortage of reliable systemic inflammatory biomarkers to predict the disease activity and progression of MS. In MS patients, a series of cytokines and chemokines promote the proliferation of neutrophils and lymphocytes and their transfer to the central nervous system. The neutrophil-to-lymphocyte ratio (NLR), which combines the information of the inherent and adaptive parts of the immune system, represents a reliable measure of the inflammatory burden. In this review, we aimed to discuss the inflammatory response in MS, mainly the function of lymphocytes and neutrophils, which can be implemented in the utility of NLR as a diagnostic tool in MS patients. The underlying pathophysiology is highlighted to identify new potential targets for neuroprotection and to develop novel therapeutic strategies.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9629953/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40669100","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Implication of High Body Fat Percentage on Migraine Chronification in Premenopausal Females","authors":"P. Ojha, V. Malhotra","doi":"10.1155/2022/8219254","DOIUrl":"https://doi.org/10.1155/2022/8219254","url":null,"abstract":"Background Chronic migraine, being a debilitating headache disorder, needs assessment of the risk factors implicated in its occurrence. We investigated the potential role of obesity as a risk for chronic migraine in premenopausal females with episodic migraine. Methods In this analytical study, body fat% was compared between episodic and chronic migraine patient groups. The standard criteria of the international classification of headache disorder were used for the diagnosis. Demographic data, clinical details of migraine, and anthropometric measurements were collected using structured questions and standardized techniques. Pearson's correlation (r) was estimated to assess the concordance between body fat% and migraine frequency. High body fat%'s implication on chronic migraine which was adjusted for body mass index (BMI), and the use of oral contraceptives was determined using logistic regression analysis. Results A total of 168 premenopausal female migraineurs, with a mean (Standard deviation) age of 33.0 (±9.0) years, were enrolled in the study. BMI and high body fat% were significantly associated with chronic migraine (p < 0.05). There was a weak positive, but significant, correlation between body fat% and migraine frequency (r = 0.185, p < 0.017). The presence of high body fat was found to increase the risk of chronic migraine by 2.8 times (confidence interval 1.4–5.6; p < 0.003). Conclusion The amount of fat mass in the body relates to the clinical characteristics of migraine. There is an increased risk of developing chronic migraine in patients having high body fat. Weight control measures can be targeted for the prevention of migraine worsening.","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-10-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87790059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Managing Chronic Neuropathic Pain: Recent Advances and New Challenges.","authors":"Namrata Hange, Sujan Poudel, Saleha Ozair, Trissa Paul, Meghna Nambakkam, Rakchhya Shrestha, Farrah Greye, Sangam Shah, Yagya Raj Adhikari, Sangharsha Thapa, Pooja Patel","doi":"10.1155/2022/8336561","DOIUrl":"https://doi.org/10.1155/2022/8336561","url":null,"abstract":"<p><strong>Aim: </strong>Neuropathic pain affects 7-10% of the population, with most of the patients receiving inadequate and incomplete treatment. Owing to the high financial burden and the poor quality of life of the patients and their caretakers, there is a dire need to address the challenges in diagnosing and treating chronic neuropathic pain.</p><p><strong>Methods: </strong>This literature review was conducted to review novel treatments and related challenges through a systematic search from sources such as PubMed, Google Scholar with the combination of MESH words such as neuropathic pain, management of neuropathic pain. Articles from non-English literature, reports without human subjects, animal studies, and abstracts/posters were excluded. However, human studies and studies published in English were included.</p><p><strong>Result: </strong>This review article discusses novel treatment modalities while acknowledging the challenges medical workers face while encountering neuropathic pain. Despite the recent advances in diagnosis and treatment modalities, several challenges still exist. Hence, there is still a need to explore the various treatment modalities, emphasizing the cause and underlying pathophysiology of neuropathic pain.</p><p><strong>Conclusion: </strong>We recommend integrated multimodal treatment with the current treatment facility, including various medical disciplines. However, a personalized approach would work the best depending on the 'patient's medical history. Therefore, this article recommends an integrated, cause-specific, cost-effective approach to address this problem of chronic neuropathic pain.</p>","PeriodicalId":19124,"journal":{"name":"Neurology Research International","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2022-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9581623/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40567737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}